These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 11817971)

  • 21. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Very low level viraemia and risk of virological failure in treated HIV-1-infected patients.
    Teira R; Vidal F; Muñoz-Sánchez P; Geijo P; Viciana P; Ribera E; Domingo P; Castaño M; Martínez E; Roca B; Puig T; Estrada V; Deig E; Galindo MJ; de la Fuente B; Lozano F; Montero M; Muñoz-Sanz A; Sanchez T; Terrón A; Romero-Palacios A; Lacalle JR; Garrido M; Suárez-Lozano I;
    HIV Med; 2017 Mar; 18(3):196-203. PubMed ID: 27476742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
    J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment interruptions in HIV-infected subjects.
    Bongiovanni M; Casana M; Tincati C; d'Arminio Monforte A
    J Antimicrob Chemother; 2006 Sep; 58(3):502-5. PubMed ID: 16816398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Virological and immunological effects of salvage therapy following treatment interruption and a shift in HIV-1 resistance genotype.
    Izopet J; Souyris C; Sandres-Sauné K; Puissant B; Obadia M; Pasquier C; Puel J; Blancher A; Massip P
    J Med Virol; 2002 Nov; 68(3):305-10. PubMed ID: 12226815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study.
    Capetti A; Meraviglia P; Landonio S; Sterrantino G; Di Biagio A; Lo Caputo S; Ammassari A; Menzaghi B; De Socio GV; Franzetti M; Soria A; Meschiari M; Sasset L; Pellicanò G; Mazzotta E; Trezzi M; Celesia BM; Melzi S; Carenzi L; Ricci E; Rizzardini G
    Int J Antimicrob Agents; 2014 Feb; 43(2):189-94. PubMed ID: 24315315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study).
    Castagna A; Muccini C; Galli L; Bigoloni A; Poli A; Spagnuolo V; Nozza S; Racca S; Galli A; Cinque P; Carini E; Lazzarin A
    J Antimicrob Chemother; 2019 Jul; 74(7):2039-2046. PubMed ID: 31225610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
    Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
    JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prospective randomized controlled trial of structured treatment interruption in HIV-infected patients failing highly active antiretroviral therapy (Canadian HIV Trials Network Study 164).
    Walmsley SL; Thorne A; Loutfy MR; LaPierre N; MacLeod J; Harrigan R; Trottier B; Conway B; Hay JR; Singer J; Zarowny D
    J Acquir Immune Defic Syndr; 2007 Aug; 45(4):418-25. PubMed ID: 17468667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.
    Katlama C; Assoumou L; Valantin MA; Soulié C; Duvivier C; Chablais L; Kolta S; Pialoux G; Mercié P; Simon A; Costagliola D; Peytavin G; Marcelin AG;
    J Antimicrob Chemother; 2014 Jun; 69(6):1648-52. PubMed ID: 24535278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study.
    Yerly S; Kaiser L; Perneger TV; Cone RW; Opravil M; Chave JP; Furrer H; Hirschel B; Perrin L
    AIDS; 2000 Feb; 14(3):243-9. PubMed ID: 10716500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can structured treatment interruptions (STIs) be used as a strategy to decrease total drug requirements and toxicity in HIV infection?
    Walmsley S; Loutfy M
    J Int Assoc Physicians AIDS Care (Chic); 2002; 1(3):95-103. PubMed ID: 12942682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.
    Cardiello PG; Hassink E; Ananworanich J; Srasuebkul P; Samor T; Mahanontharit A; Ruxrungtham K; Hirschel B; Lange J; Phanuphak P; Cooper DA
    Clin Infect Dis; 2005 Feb; 40(4):594-600. PubMed ID: 15712083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection.
    Hazra R; Gafni RI; Maldarelli F; Balis FM; Tullio AN; DeCarlo E; Worrell CJ; Steinberg SM; Flaherty J; Yale K; Kearney BP; Zeichner SL
    Pediatrics; 2005 Dec; 116(6):e846-54. PubMed ID: 16291735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report.
    Frange P; Faye A; Avettand-Fenoël V; Bellaton E; Descamps D; Angin M; David A; Caillat-Zucman S; Peytavin G; Dollfus C; Le Chenadec J; Warszawski J; Rouzioux C; Sáez-Cirión A;
    Lancet HIV; 2016 Jan; 3(1):e49-54. PubMed ID: 26762993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects.
    Moltó J; Ruiz L; Romeu J; Martínez-Picado J; Negredo E; Tural C; Sirera G; Clotet B
    AIDS Res Hum Retroviruses; 2004 Dec; 20(12):1283-8. PubMed ID: 15650419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
    Panel de expertos de GESIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients.
    Gianotti N; Canducci F; Galli L; Cossarini F; Salpietro S; Poli A; Nozza S; Spagnuolo V; Clementi M; Sampaolo M; Ceresola ER; Racca S; Lazzarin A; Castagna A
    Clin Microbiol Infect; 2015 Jan; 21(1):103.e7-103.e10. PubMed ID: 25636935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen.
    Armenia D; Di Carlo D; Cozzi-Lepri A; Calcagno A; Borghi V; Gori C; Bertoli A; Gennari W; Bellagamba R; Castagna A; Latini A; Pinnetti C; Cicalini S; Saracino A; Lapadula G; Rusconi S; Castelli F; Di Giambenedetto S; Andreoni M; Di Perri G; Antinori A; Mussini C; Ceccherini-Silberstein F; Monforte AD; Perno CF; Santoro MM;
    Antivir Ther; 2019; 24(5):321-331. PubMed ID: 30977466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.